- Antiviral Effect of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-associated Myopathy
-
Tak WY
- KMID: 1775779
- Korean J Gastroenterol.
- 2013 Jan;61(1):1-2.
- doi: 10.4166/kjg.2013.61.1.1
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Entecavir Treatment in Hepatitis B Virus-related Decompensated Cirrhosis
-
Kim YS
- KMID: 1245203
- Korean J Gastroenterol.
- 2012 Mar;59(3):203-204.
- doi: 10.4166/kjg.2012.59.3.203
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Two Lung Masses with Different Responses to Pemetrexed
-
Park KY, Jung JW, Nam SB, Lee HJ, Kim HS, Choi YH, Lee JC
- KMID: 1785681
- Korean J Intern Med.
- 2010 Jun;25(2):213-216.
- doi: 10.3904/kjim.2010.25.2.213
We described here a patient who had two lung masses. Although the two masses had the same histology and a similar good response to initial chemotherapy with gemcitabine and carboplatin,... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictors for virologic response in management of chronic hepatitis B
-
Lee JM, Ahn SH
- KMID: 1782215
- Korean J Hepatol.
- 2010 Mar;16(1):1-4.
- doi: 10.3350/kjhep.2010.16.1.1
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
-
Kim JH, Ahn SH, Ko SY, Choe WH, Kim KH, Kwon SY
- KMID: 2373120
- Clin Mol Hepatol.
- 2016 Jun;22(2):241-249.
- doi: 10.3350/cmh.2015.0053
BACKGROUND/AIMS: Before tenofovir (TDF) become available in South Korea, combination therapy with entecavir (ETV) and adefovir (ADV) was the most potent regimen for chronic hepatitis B (CHB) patients who fail... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
-
Park JG, Park SY
- KMID: 2351024
- Clin Mol Hepatol.
- 2015 Sep;21(3):242-248.
- doi: 10.3350/cmh.2015.21.3.242
BACKGROUND/AIMS: We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
-
Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H
- KMID: 2069763
- Clin Mol Hepatol.
- 2014 Sep;20(3):267-273.
- doi: 10.3350/cmh.2014.20.3.267
BACKGROUND/AIMS: Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB). However, the long-term outcomes of LAM+ADV and... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-induced Myopathy
-
Lee JW, Lee YJ, Lee JJ, Kim JH, Jung YK, Kwon OS, Choi DJ, Kim YS, Kim JH
- KMID: 1775784
- Korean J Gastroenterol.
- 2013 Jan;61(1):30-36.
- doi: 10.4166/kjg.2013.61.1.30
BACKGROUND/AIMS: Clevudine is a potent antiviral agent against HBV. However, long-term clevudine therapy may cause myopathy. This study was carried out to identify the efficacy of entecavir switching therapy in... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study
-
Cho EY, Yim HJ, Jung YK, Suh SJ, Seo YS, Kim JH, Kim HS, Lee SH, Ahn SH, Lee JI, Jeong SH, Kim JW, Lee JW, Kim IH, Kim HS, Park SJ, Lee JM, Hwang SG
- KMID: 2412164
- Gut Liver.
- 2017 Jan;11(1):129-135.
- doi: 10.5009/gnl15597
BACKGROUND/AIMS: Data are lacking regarding the management of chronic hepatitis B (CHB) with resistance to clevudine (CLV). This study evaluated the efficacy of different rescue therapies for CLV-resistant CHB. METHODS: Patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
-
Kim DH, Choi JW, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Shin SY, Lee CK
- KMID: 2419112
- Yonsei Med J.
- 2017 May;58(3):552-556.
- doi: 10.3349/ymj.2017.58.3.552
PURPOSE: This study examined 2-year outcome of consecutive therapy using entecavir (ETV) followed by telbivudine (LdT) in subjects with undetectable hepatitis B virus (HBV) DNA level and normal alanine aminotransferase... -
- CITED
-
- Close
- SHARE
-
- Close
- Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis
-
Jwa HY, Cho YK, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU, Kim BS, Lee BW, Song BC
- KMID: 2363038
- Clin Mol Hepatol.
- 2016 Mar;22(1):183-187.
- doi: 10.3350/cmh.2016.22.1.183
Recent studies suggest that liver cirrhosis is reversible after administering oral nucleos(t)ide analogue therapy to patients with hepatitis B virus (HBV) infection. However, few studies have addressed whether esophageal varices... -
- CITED
-
- Close
- SHARE
-
- Close
- Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
-
Wi CI, Kim WR, Gross JB, Stadheim L, Poterucha
- KMID: 2412051
- Gut Liver.
- 2016 Jul;10(4):611-616.
- doi: 10.5009/gnl14256
BACKGROUND/AIMS: Despite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion. We aimed to explore... -
- CITED
-
- Close
- SHARE
-
- Close
- High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
-
Chae HB, Kim MJ, Seo EG, Choi YH, Lee HS, Han JH, Yoon SM, Park SM, Youn SJ
- KMID: 1372654
- Korean J Hepatol.
- 2012 Mar;18(1):75-83.
- doi: 10.3350/kjhep.2012.18.1.75
BACKGROUND/AIMS: Newly developed and potent antiviral agents suffer from the problem of drug resistance. Multidrug resistance is a major impediment in the treatment of patients with chronic hepatitis B (CHB).... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
-
Hwang JA, Kim KB, Yang MJ, Lim SG, Hwang JC, Cheong JY, Cho SW, Kim SS
- KMID: 2164363
- Clin Mol Hepatol.
- 2015 Jun;21(2):131-140.
- doi: 10.3350/cmh.2015.21.2.131
BACKGROUND/AIMS: To determine the efficacies of entecavir (ETV) in nucleos(t)ide analogue (NA)-naive chronic hepatitis B (CHB) patients and in those with prior lamivudine (LAM) use who did not develop resistance. METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data
-
Kim JH, Choi YJ, Moon HW, Ko SY, Choe WH, Kwon SY
- KMID: 1730887
- Clin Mol Hepatol.
- 2013 Dec;19(4):409-416.
- doi: 10.3350/cmh.2013.19.4.409
BACKGROUND/AIMS: Quantification of the hepatitis B surface antigen (HBsAg) is increasingly used to determine the treatment response in patients with chronic hepatitis B (CHB). However, there are limited data about... -
- CITED
-
- Close
- SHARE
-
- Close
- Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
-
Kim H, Yun T, Lee YJ, Han JY, Kim HT, Lee GK
- KMID: 1777655
- J Korean Med Sci.
- 2013 Nov;28(11):1595-1602.
- doi: 10.3346/jkms.2013.28.11.1595
Most patients with tyrosine kinase inhibitor (TKI)-sensitive non-small cell lung cancer (NSCLC) eventually develop acquired resistance to TKIs. Factors that affect TKI-sensitive patient survival after progression during TKI treatment remain... -
- CITED
-
- Close
- SHARE
-
- Close
- Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma
-
Kim JH, Sinn DH, Kim K, Kim H, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW
- KMID: 2412100
- Gut Liver.
- 2016 Nov;10(6):939-947.
- doi: 10.5009/gnl15527
BACKGROUND/AIMS: Antiviral therapy is a key component in the management of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. However, whether the potent drug entecavir is more effective than a... -
- CITED
-
- Close
- SHARE
-
- Close
- Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
-
Ahn SH, Chun JY, Shin SK, Park JY, Yoo W, Hong SP, Kim SO, Han KH
- KMID: 1730886
- Clin Mol Hepatol.
- 2013 Dec;19(4):399-408.
- doi: 10.3350/cmh.2013.19.4.399
BACKGROUND/AIMS: Molecular diagnostic methods have enabled the rapid diagnosis of drug-resistant mutations in hepatitis B virus (HBV) and have reduced both unnecessary therapeutic interventions and medical costs. In this study... -
- CITED
-
- Close
- SHARE
-
- Close
- Genotypic resistance to entecavir in chronic hepatitis B patients
-
Kim BU, Goo JC, Park BC, Kim SO, Hong SP, Jeong JI, Chae HB, Park SM, Youn SJ
- KMID: 1792593
- Korean J Hepatol.
- 2010 Jun;16(2):147-157.
- doi: 10.3350/kjhep.2010.16.2.147
BACKGROUND/AIMS: The prevalence and clinical characteristics of entecavir (ETV) resistance is not well known. The aim of this study was to determine the frequency of genotypic resistance in nonresponders and... -
- CITED
-
- Close
- SHARE
-
- Close
- Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization
-
Yoo SH, Jang JW, Kwon JH, Jung SM, Jang B, Choi JY
- KMID: 2373150
- Clin Mol Hepatol.
- 2016 Dec;22(4):458-465.
- doi: 10.3350/cmh.2016.0054
BACKGROUND/AIMS: Hepatic damage during transarterial chemoembolization (TACE) is a critical complication in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Apart from its role in preventing HBV reactivation, there... -
- CITED
-
- Close
- SHARE
-
- Close
